康希通信(688653.SH):上半年研發費用同比增速較大
格隆匯7月31日丨康希通信(688653.SH)近日在接待機構投資者調研時表示,公司2024年上半年研發費用同比增速較大,全年研發投入較去年同期預計增幅明顯。主要原因有兩個:其一,對募投項目的持續投入;其二,加強了與國內供應商的合作,完善供應鏈國產化的各個環節。公司是一家專業的射頻前端芯片設計企業,採用Fabless無晶圓模式,晶圓製造、封裝和測試環節都分別委託給專業廠商完成。研發型企業不同於生產型企業,其在運營過程中無需大量購置固定資產。目前公司的固定資產主要為實驗室研發調試設備及放置在委外加工廠保證產能用的測試設備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.